Association of promyelocytic leukemia protein with expression of IL-6 and resistance to treatment in multiple myeloma

Daisuke Ohgiya, Hiromichi Matsushita, Makoto Onizuka, Naoya Nakamura, Jun Amaki, Yasuyuki Aoyama, Hidetsugu Kawai, Yoshiaki Ogawa, Hiroshi Kawada, Kiyoshi Ando

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Background/Aims: Promyelocytic leukemia protein (PML) was originally identified as a tumor suppressor but has been recently shown to have the ability to control stem cell function in multiple tissues including malignancies. This study aimed to evaluate the biological and clinical significance of PML in multiple myeloma (MM). Methods: We knocked down PML in myeloma cells with a lentiviral vector expressing microRNA to target PML, which were used for in vitro analyses. We also evaluated the association between PML expression in the bone marrow and patients' clinical parameters. Results: The expression of IL-6 was decreased in myeloma cells with knocked-down PML expression. Immunohistochemical study showed that the PML expression level varied widely in the bone marrow of 48 MM patients, and that IL-6 expression correlated with PML expression in these patients. In addition, MM with high PML expression at diagnosis showed a poor prognosis regarding the 2-year survival, and PML and IL-6 positivity increased with the progression of disease in 13 sequentially analyzed cases. Conclusions: These results suggest that PML expression was positively associated with IL-6 expression in patients and was also related to tumor development and resistance to treatment in MM.

Original languageEnglish
Pages (from-to)213-222
Number of pages10
JournalActa Haematologica
Issue number4
Publication statusPublished - 2012 Nov
Externally publishedYes


  • Chemokines
  • Cytokines
  • Interleukin-6
  • Multiple myeloma
  • Promyelocytic leukemia

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Association of promyelocytic leukemia protein with expression of IL-6 and resistance to treatment in multiple myeloma'. Together they form a unique fingerprint.

Cite this